Federal government reviewing new vaccine thought to be effective against COVID-19 variants
The federal government is reviewing a new COVID-19 vaccine that has been submitted for regulatory approval.
Maryland-based Novavax quietly applied on Friday for Health Canada to approve its vaccine, which studies have suggested is effective against the British and South African variants of the virus.
The application comes less than two weeks after Ottawa finalized an agreement with the company for 52 million doses of the vaccine, with an option to purchase another 24 million.
The regulatory review also comes as Ottawa continues pressing the European Union on new controls on the export of vaccines from the continent.
International Trade Minister Mary Ng spoke to her European counterpart for the second time in three days on Saturday as part of a broader effort to ensure vaccines bound for Canada will not be affected.
The EU's new export controls come amid reduced shipments of the Pfizer-BioNTech vaccine because of a temporary shutdown of its plant in Belgium.
- Canada’s vaccine deliveries further threatened as Europe mulls export controls
- Canada to get two million Pfizer-BioNTech vaccine doses as provinces expand rollouts
- First doses of Pfizer COVID-19 vaccine, not yet approved, to land in Canada next week
- Canada to receive 2.4 million doses of COVID-19 vaccine this week
- Health Canada to announce approval of Johnson and Johnson vaccine against COVID-19
- Photo radar begins in Mississauga next month at these locations
- 2 winning tickets for Saturday’s $6 million Lotto 649 jackpot
- Two Mississauga 16-year-olds arrested for burning Pride flag
- Swiss Chalet set to re-open in Mississauga after closing down for a while
- Killer rapist Paul Bernardo faces parole hearing today; victim families opposed